Senior Manager, Specialty Pharmacy Business and Operations
About the job
- A bachelor's degree in pharmacy, pharmaceutical sciences, healthcare administration, business, operations management, or a related field, or equivalent experience is required.
- At least 10 years of experience in pharmacy operations, pharmacy support, healthcare supply chain/medication distribution, or a related field is required.
- At least 5 years of experience in a management capacity is required.
- Direct specialty pharmacy support and operations to deliver service, quality, compliance, and operational performance outcomes aligned to client departmental objectives.
- Orchestrate strategic planning, cross-team execution, workforce planning, and service governance to maintain consistent throughput, operational continuity, and customer experience across specialty pharmacy services.
- Shape workflow standards, escalation frameworks, and performance controls to strengthen process reliability, patient and provider satisfaction, and patient safety.
- Champion operational improvements, technology enablement, and leadership capability development to scale service delivery and sustain long-term operational effectiveness.
- Drive the strategic direction of the specialty pharmacy business by identifying emerging growth opportunities and developing the business cases, operational frameworks, and stakeholder alignment needed to move from concept to execution.
- Direct cross-functional coordination across pharmacy operations, fulfillment, inventory, customer support, and technology teams to ensure seamless service execution.
- Establish governance routines, escalation pathways, and operational controls to strengthen audit readiness, regulatory compliance, and service consistency.
- Drive transformation of workflows, onboarding practices, and operational routines to improve throughput, reduce rework, and standardize execution across teams and sites.
- Optimize operational resource allocation, staffing coverage, and service capacity to balance delivery performance, cost efficiency, and risk management.
- Influence senior stakeholders using operational metrics, trend analysis, customer feedback, and performance reporting to support decision-making and prioritization.
- Standardize workflow systems, case management practices, and operational reporting to improve visibility, traceability, and operational discipline.
- Resolve escalated operational issues and negotiate cross-functional trade-offs impacting service delivery, customer experience, or operational continuity.
- A master's degree in business administration, healthcare administration, operations management, customer experience, or a related field, or equivalent experience is preferred.
- Certification in customer experience, customer success, project management, service management, process improvement, or equivalent is preferred.
About the company
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Conshohocken, Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 Q3 revenue rose 5.1% to $84.8 billion; EPS beat estimates.
- Cencora repurchased $1 billion shares in Q3 2026 and raised fiscal 2026 guidance.
- June 17 and September 2, 2026 launches expand high-growth specialty and cell-therapy services.
What critics are saying
- March 31, 2026 accrued opioid liability remained $4.3 billion, payable over 13 years.
- Baltimore’s October 2025 verdict was vacated in April 2026, but opioid litigation persists.
- ASP rule changes and specialty-logistics competition can compress margins and derail oncology economics.
What makes Cencora unique
- Cencora embeds inside oncology through OneOncology and RCA, strengthening provider switching costs.
- June 17, 2026 Nucleus and September 2, 2026 CGT Enablement deepen workflow integration.
- Global distribution scale and specialty services create a rare pharma-plus-services moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.
Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.
Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.